Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May;97(5):E176-E180.
doi: 10.1002/ajh.26502. Epub 2022 Feb 25.

Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model

Stefano Molica  1 , Diana Giannarelli  2 , Andrea Visentin  3 , Gianluigi Reda  4 , Paolo Sportoletti  5 , Anna Maria Frustaci  6 , Annalisa Chiarenza  7 , Stefania Ciolli  8 , Candida Vitale  9 , Luca Laurenti  10 , Lorenzo De Paoli  11 , Roberta Murru  12 , Massimo Gentile  13 , Riccardo Moia  11 , Gian Matteo Rigolin  14 , Luciano Levato  1 , Annamaria Giordano  15 , Giovanni Del Poeta  16 , Caterina Stelitano  17 , Marina Deodato  6 , Claudia Ielo  18 , Alessandro Noto  4 , Valerio Guarente  5 , Marta Coscia  9 , Alessandra Tedeschi  6 , Gianluca Gaidano  11 , Antonio Cuneo  14 , Robin Foa'  18 , Livio Trentin  3 , Francesca Romana Mauro  18
Affiliations
Free article

Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model

Stefano Molica et al. Am J Hematol. 2022 May.
Free article
No abstract available

PubMed Disclaimer

References

REFERENCES

    1. Molica S, Seymour JF, Polliack A. A perspective on prognostic models in chronic lymphocytic leukemia in the era of targeted agents. Hematol Oncol. 2021;39(5):595-604.
    1. Burger JA. Treatment of chronic lymphocytic leukemia. N Engl J Med. 2020;383(5):460-473.
    1. Kittai AS, Miller C, Goldstein D, et al. The impact of increasing karyotypic complexity and evolution on survival in patients with CLL treated with ibrutinib. Blood. 2021;138(23):2372-2382.
    1. Rigolin GM, Del Giudice I, Bardi A, et al. Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab: the GIMEMA LLC1114 phase 2 study. Blood. 2021;138(25):2727-2730.
    1. International CLL-IPI Working Group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779-790.

MeSH terms

LinkOut - more resources